Literature DB >> 30257183

Serotonin2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons.

Adeline Cathala1, Céline Devroye2, Guillaume Drutel3, Jean-Michel Revest4, Francesc Artigas5, Umberto Spampinato6.   

Abstract

The central serotonin2B receptor (5-HT2BR) is a well-established modulator of dopamine (DA) neuron activity in the rodent brain. Recent studies in rats have shown that the effect of 5-HT2BR antagonists on accumbal and medial prefrontal cortex (mPFC) DA outflow results from a primary action in the dorsal raphe nucleus (DRN), where they activate 5-HT neurons innervating the mPFC. Although the mechanisms underlying this interaction remain largely unknown, data in the literature suggest the involvement of DRN GABAergic interneurons in the control of 5-HT activity. The present study examined this hypothesis using in vivo (intracerebral microdialysis) and in vitro (immunohistochemistry coupled to reverse transcription-polymerase chain reaction) experimental approaches in rats. Intraperitoneal (0.16 mg/kg) or intra-DRN (1 μM) administration of the selective 5-HT2BR antagonist RS 127445 increased 5-HT outflow in both the DRN and the mPFC, these effects being prevented by the intra-DRN perfusion of the GABAA antagonist bicuculline (100 μM), as well as by the subcutaneous (0.16 mg/kg) or the intra-DRN (0.1 μM) administration of the selective 5-HT1AR antagonist WAY 100635. The increase in DRN 5-HT outflow induced by the intra-DRN administration of the selective 5-HT reuptake inhibitor citalopram (0.1 μM) was potentiated by the intra-DRN administration (0.5 μM) of RS 127445 only in the absence of bicuculline perfusion. Finally, in vitro experiments revealed the presence of the 5-HT2BR mRNA on DRN GABAergic interneurons. Altogether, these results show that, in the rat DRN, 5-HT2BRs are located on GABAergic interneurons, and exert a tonic inhibitory control on 5-HT neurons innervating the mPFC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-HT release; 5-HT(2B) receptor; Dorsal raphe; Immunohistochemistry; In vivo microdialysis; Medial prefrontal cortex; RT-PCR

Mesh:

Substances:

Year:  2018        PMID: 30257183     DOI: 10.1016/j.expneurol.2018.09.015

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  3 in total

1.  New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties.

Authors:  Chungping Yu; Jennie Garcia-Olivares; Shawn Candler; Stefan Schwabe; Vladimir Maletic
Journal:  J Exp Pharmacol       Date:  2020-08-25

Review 2.  Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Authors:  Robert L Findling; Shawn A Candler; Azmi F Nasser; Stefan Schwabe; Chungping Yu; Jennie Garcia-Olivares; Welton O'Neal; Jeffrey H Newcorn
Journal:  CNS Drugs       Date:  2021-05-18       Impact factor: 5.749

3.  Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition.

Authors:  Rami Hamati; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2020-05-30       Impact factor: 7.853

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.